

Non-clinical development of ALS disease treatment using a small molecule compound that inhibits aggregation of SOD1 protein

PRG S&Tech Inc.



NEUROSCIENCE	Preclinical
Product Type	Small molecule
Indication	Amyotrophic Lateral Sclerosis(ALS)
Target	SOD1 misfolding/aggregation
MoA(Mechanism of Action)	PRG-A-04 binding to abnormal SOD1 trimer structure inhibits the pathogenic aggregation initiated from the trimer structure
Competitiveness	PRG-A-04 selectively binds to SOD1 trimer induced by SOD1 mutation. It does not block the formation of SOD1 dimer, the functionally active form. It means a high possibility that high concentrations of drugs and long-term use will not cause side effects. PRG-A-04 shows high permeability to BBB and develops as an oral administration agent that increases the convenience of administration.
Development Stage	Preclinical
Route of Administration	Oral